Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Buys Rights To ArQule Cancer Drug Still In Trials

This article was originally published in PharmAsia News

Executive Summary

Daiichi Sankyo and ArQule of the United States have joined forces to develop cancer drugs, beginning with a $75 million investment. The upfront payment by Daiichi is for rights to ArQule's ARQ 197 c-Met inhibitor for liver and other cancers, now in clinical trials in the U.S. The purchase gives Daiichi rights only in China, Taiwan and South Korea, and not in Japan. Trials so far have shown effectiveness for the drug without severe side effects. (Click here for more - a subscription may be required

You may also be interested in...



What COVID Spotlight Means For Pharma – In Their Own Words

Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem. 

Deal Watch: Bristol Teams Up With Insitro, Sensyne In AI-Directed Collaborations

Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.

Early Research Suggests Wearables Can Spot Early Signs Of COVID-19; Fitbit Receives $2.5m Army Award

A consortium of researchers, including Fitbit, are developing algorithms to spot COVID-19 before people become ill.

UsernamePublicRestriction

Register

ID1132356

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel